Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ABL DiagnosticsXPAR:ABLD -6.98%50 Earnings per Share (Diluted) is €0.06 as of Dec. 2025. GuruFocus rates XPAR:ABLD with a GF Score™ of 50/100 and a GF Value™ of €8.41 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 502 Healthcare Providers & Services companies, ABL Diagnostics ranks better than 53.59% on this metric.
ABL Diagnostics's EPS (Basic) for the
six
months ended in Dec. 2025 was €0.04.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.06.
During the past 12 months, ABL Diagnostics's average EPS without NRIGrowth Rate was 342.90% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 13.00% per year.
During the past 13 years, ABL Diagnostics's highest 3-Year average EPS without NRI Growth Rate was 32.40% per year. The lowest was -30.30% per year. And the median was 13.00% per year.
ABL Diagnostics (XPAR:ABLD) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
ABL Diagnostics Earnings per Share (Diluted) Related Terms
ABL Diagnostics Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABL Diagnostics Earnings per Share (Diluted) Chart
XPAR:ABLD vs VEEV, BTSG, TEM: Earnings per Share (Diluted) Comparison
For the Health Information Services subindustry, ABL Diagnostics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics PE Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's PE Ratio distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's PE Ratio falls into.
ABL Diagnostics Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
ABL Diagnostics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.06
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of €0.06 mean?
ABL Diagnostics (XPAR:ABLD) has a Earnings per Share (Diluted) of €0.06 as of Dec. 2025. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on ABL Diagnostics and its competitors. According to the industry distribution chart, ABL Diagnostics ranks #233 out of 502 companies in the Healthcare Providers & Services industry, placing it in the top 46.4%.
Is ABL Diagnostics' Earnings per Share (Diluted) too high?
ABL Diagnostics' current Earnings per Share (Diluted) is €0.06. Based on the distribution chart, ABL Diagnostics ranks #233 out of 502 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, ABL Diagnostics has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' Earnings per Share (Diluted) compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #233 out of 502 companies for Earnings per Share (Diluted). This puts ABL Diagnostics in the upper half of its industry. The industry median Earnings per Share (Diluted) is 10.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Healthcare Providers & Services company?
The median Earnings per Share (Diluted) among Healthcare Providers & Services companies is 10.90, based on 502 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median Earnings per Share (Diluted) is 10.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current Earnings per Share (Diluted) is €0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €8.41, compared to a current price of €2.40 — trading 71.5% below its estimated fair value. The current Earnings per Share (Diluted) is €0.06. ABL Diagnostics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current Earnings per Share (Diluted) is €0.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.40 is trading 71.5% below its estimated GF Value™ of €8.41.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for XPAR:ABLD:
Earnings per Share (Diluted): €0.06
GF Value™: €8.41 vs. price of €2.40 (71.5% below fair value)
No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
50GF Score
Get the complete analysis for XPAR:ABLD
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ABLD has been successfully added to your 
